Key Points
- Mirum Pharmaceuticals SVP Jolanda Howe sold 1,840 shares for $193,733.60 at an average price of $105.29, reducing her holdings by 59.09% to 1,274 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Mirum reported quarterly revenue of $176.24 million, up 37.9% year over year and above analyst expectations, but posted an adjusted loss of $1.06 per share, missing the consensus estimate of a $0.74 loss.
- Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $143.40, compared with the stock’s reported price near $105.79.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 1,840 shares of the business's stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $105.29, for a total value of $193,733.60. Following the sale, the senior vice president owned 1,274 shares in the company, valued at $134,139.46. This represents a 59.09% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jolanda Howe also recently made the following trade(s):
- On Wednesday, July 1st, Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $120.00, for a total value of $326,520.00.
- On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $101.95, for a total value of $264,458.30.
Mirum Pharmaceuticals Stock Performance
Mirum Pharmaceuticals stock opened at $105.79 on Thursday. The business has a 50 day moving average of $110.46 and a 200-day moving average of $101.77. The company has a market capitalization of $6.45 billion, a P/E ratio of -7.77 and a beta of 0.52. Mirum Pharmaceuticals, Inc. has a 1 year low of $50.25 and a 1 year high of $130.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The business had revenue of $176.24 million for the quarter, compared to analyst estimates of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The firm's quarterly revenue was up 37.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.12) earnings per share. On average, equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.
Analysts Set New Price Targets
MIRM has been the subject of several analyst reports. Evercore reaffirmed an "outperform" rating and set a $138.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Morgan Stanley upped their price target on Mirum Pharmaceuticals from $140.00 to $150.00 and gave the company an "overweight" rating in a research report on Thursday, June 11th. Weiss Ratings cut Mirum Pharmaceuticals from a "sell (d)" rating to a "sell (d-)" rating in a research note on Tuesday, June 23rd. Stifel Nicolaus set a $136.00 price objective on Mirum Pharmaceuticals in a research report on Thursday, May 7th. Finally, CLSA set a $146.00 price objective on Mirum Pharmaceuticals in a research note on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $143.40.
Check Out Our Latest Stock Analysis on Mirum Pharmaceuticals
Hedge Funds Weigh In On Mirum Pharmaceuticals
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC grew its stake in Mirum Pharmaceuticals by 21.4% during the fourth quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company's stock worth $479,050,000 after purchasing an additional 1,067,722 shares during the period. State Street Corp grew its position in shares of Mirum Pharmaceuticals by 59.2% during the 4th quarter. State Street Corp now owns 2,143,992 shares of the company's stock worth $169,354,000 after buying an additional 797,088 shares during the period. Wellington Management Group LLP increased its stake in shares of Mirum Pharmaceuticals by 566.8% in the 3rd quarter. Wellington Management Group LLP now owns 790,689 shares of the company's stock valued at $57,965,000 after acquiring an additional 672,118 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of Mirum Pharmaceuticals by 709.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company's stock valued at $44,889,000 after acquiring an additional 536,674 shares during the period. Finally, Voloridge Investment Management LLC boosted its stake in Mirum Pharmaceuticals by 2,116.6% during the third quarter. Voloridge Investment Management LLC now owns 389,574 shares of the company's stock worth $28,560,000 after acquiring an additional 371,999 shares in the last quarter.
Mirum Pharmaceuticals Company Profile
(
Get Free Report)
Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.
Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
